Cabotegravir 600mg/3ml prolonged-release suspension for injection vials
NHS hospitals in England used £17,958,891 of indicative cost of Cabotegravir 600mg/3ml prolonged-release suspension for injection vials in the 12 months to July 2026, about 0.1% of all hospital medicines spend. That is up 55.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Cabotegravir 600mg/3ml prolonged-release suspension for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Cabotegravir 600mg/3ml prolonged-release suspension for injection vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Chelsea & Westminster Hospital Nhs Ft | £2,140,272 |
| Barts Health Nhs Trust | £1,386,149 |
| Western Sussex Hospitals Nhs Found Trust | £1,119,214 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,054,575 |
| Royal Free London Nhs Foundation Trust | £883,401 |
| Aintree University Hospital Nhs Ft | £854,672 |
| Manchester University Nhs Ft | £768,487 |
| Imperial College Healthcare Nhs Trust | £743,349 |
| Walsall Healthcare Nhs Trust | £535,068 |
| University College London Foundation Tr | £472,823 |
The primary-care picture
Cabotegravir is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Cabotegravir medicine page.